Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
A phase 3 trial of Azacitidine, Venetoclax, Decitabine and Cytarabine in acute myeloid leukaemia, run by Sellas Life Sciences Group, active and no longer recruiting.
Overview
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 is a phase 3 interventional study registered as NCT04229979 by Sellas Life Sciences Group, with 127 participants enrolled, started 2021-02-08 and due to reach its primary completion in 2025-12. Interventions recorded: Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine and GM-CSF.
Similar pages
not linked directly; found by shared links- TrialStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Shares Galena Biopharma, Azacitidine, Venetoclax and the tag pipeline.
- TrialA Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Shares Cytarabine, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialStudies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Shares Cytarabine, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Shares Decitabine, Azacitidine and the tag pipeline.
- TrialClinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Shares Decitabine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.